Literature DB >> 3197819

Hypocholesterolemia in acute myelogenous leukemia.

J C Reverter1, J Sierra, J M Martí-Tutusaus, E Montserrat, A Grañena, C Rozman.   

Abstract

Plasma-cholesterol concentrations were determined in 85 acute myelogenous leukemia patients. Measurements were repeated in 28 cases during remission. Mean plasma-cholesterol concentration (+/- SD) at diagnosis was 3.95 mmol/l (+/- 1.29). 47 patients (55.3%) had hypocholesterolemia (less than 3.87 mmol/l). Among the main clinical, hematologic and biochemical parameters, only high leukocyte counts were correlated with hypocholesterolemia. As far the FAB subtypes are concerned, the lowest cholesterol levels were observed in leukemias with monocytic component. However, although the same FAB subtypes showed significantly higher leucocytes counts than the other subtypes, both parameters were independently related to low cholesterol levels. Remission was associated with a significant increase in cholesterol levels in those patients with low cholesterol concentrations or high leukocyte counts at diagnosis. These results support the idea that initial hypocholesterolemia in acute myelogenous leukemia is related to the tumoral mass present at diagnosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3197819     DOI: 10.1111/j.1600-0609.1988.tb00203.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  6 in total

1.  Elevated lipoprotein(a) levels in patients with acute myeloblastic leukaemia decrease after successful chemotherapeutic treatment.

Authors:  A Niendorf; A Stang; U Beisiegel; A Peters; H Nägele; A Gebhardt; R Kuse
Journal:  Clin Investig       Date:  1992-08

2.  Lipid profile in leukemia and Hodgkin's disease.

Authors:  P P Naik; M S Ghadge; A S Raste
Journal:  Indian J Clin Biochem       Date:  2006-09

3.  Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies.

Authors:  M R Law; S G Thompson
Journal:  Cancer Causes Control       Date:  1991-07       Impact factor: 2.506

Review 4.  Lipoprotein Drug Delivery Vehicles for Cancer: Rationale and Reason.

Authors:  Jaideep Chaudhary; Joseph Bower; Ian R Corbin
Journal:  Int J Mol Sci       Date:  2019-12-15       Impact factor: 5.923

5.  Perturbations of triglycerides but not of cholesterol metabolism are prevented by anti-tumour necrosis factor treatment in rats bearing an ascites hepatoma (Yoshida AH-130).

Authors:  S Dessì; B Batetta; O Spano; G J Bagby; L Tessitore; P Costelli; F M Baccino; P Pani; J M Argilès
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

6.  PEGylated IL-10 Activates Kupffer Cells to Control Hypercholesterolemia.

Authors:  Ivan H Chan; Dennis Van Hoof; Marina Abramova; Melissa Bilardello; Elliot Mar; Brett Jorgensen; Scott McCauley; Harminder Bal; Martin Oft; Peter Van Vlasselaer; John B Mumm
Journal:  PLoS One       Date:  2016-06-14       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.